Treatment gaps in osteoporosis care following recurrent fractures: a nationwide cohort study
Open Access
- 1 September 2026
- journal article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (9)
Abstract
Aim: This nationwide cohort study primarily aimed to descriptively characterize real-world treatment patterns, including treatment initiation, adherence, treatment duration and discontinuation of the first treatment drug, among patients who experienced a recurrent osteoporotic fracture. Materials & methods: This population-based, retrospective cohort study used data from the Health Insurance Review and Assessment Database of South Korea. It included male and female patients aged 55 years and older who experienced a recurrent osteoporotic fracture within 2 years of their index fracture in 2013. Results: The study period was from 1 January 2012 to 31 December 2021, with an outcome assessment period from 1 January 2013 to 31 December 2017. A total of 34,558 patients with recurrent osteoporotic fractures were observed, and just over half (n = 18,462, 53.4%) received osteoporosis medication, with a significant difference in medication rates between males (23.7%) and females (58.8%) (p < 0.001). The estimated median duration of osteoporosis medication was 146 days (interquartile range: 61–365 days). The discontinuation rate of medication within 2 years of follow-up after their recurrent fracture was 80.5%, with the highest discontinuation rate (90.4%) observed among patients taking daily oral bisphosphonate medication. Conclusion: Although patients with recurrent fractures require intensive management, our results showed a significant unmet need in the initiation and persistence of osteoporosis medication. Therefore, it is crucial to establish a strategic treatment approach to address the treatment gap in managing osteoporosis among very high-risk patients. Dataset name: Health Insurance Review and Assessment Database of South Korea.Keywords
This publication has 51 references indexed in Scilit:
- Defining Very High Fracture Risk: Is FRAX Fit for Purpose?Journal of Bone and Mineral Research, 2020
- Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of InitiationJAMA Network Open, 2019
- Effect of Negative Pressure Wound Therapy vs Standard Wound Management on 12-Month Disability Among Adults With Severe Open Fracture of the Lower LimbJAMA, 2018
- Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycleOsteoporosis International, 2013
- Making the first fracture the last fracture: ASBMR task force report on secondary fracture preventionJournal of Bone and Mineral Research, 2012
- Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistenceOsteoporosis International, 2008
- Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumabPediatric Pulmonology, 2006
- Methods for evaluation of medication adherence and persistence using automated databasesPharmacoepidemiology and Drug Safety, 2006
- Fracture risk following an osteoporotic fractureOsteoporosis International, 2003
- Risk of New Vertebral Fracture in the Year Following a FractureJAMA, 2001